TransCode board launches strategic review of company and oncology portfolio

RNAZ•2026-10-28

TransCode Therapeutics' board initiated a formal strategic review to maximize value, considering asset licensing or sales, development partnerships and other transactions. Tungsten Advisors was retained as exclusive strategic financial adviser.

TransCode board launches strategic review of company and oncology portfolio

1. Strategic review

Related News

Google and Microsoft weave tangled AI webs

Nano-X Imaging CFO Guy Nathansohn steps down for medical reasons

DMC Global presents strategy focused on debt reduction

Sources

TransCode board launches strategic review of company and oncology portfolio

Encompass Health raises 2026 adjusted EPS outlook to $6.23-$6.37

Cipher Digital plans to attend seven investor and industry conferences